

30 April 2026

CARETEQ'S Q3 FY26 ACTIVITIES REPORT AND APPENDIX 4C

Positive operating cash flow; EHS divestment completed ; Careteq refocuses on HMR Referrals

Careteq Limited (ASX: CTQ) ("Careteq" or "the Company"), a clinical healthtech company specialising in innovative solutions for the home care and disability sector, is pleased to provide the following quarterly update and commentary on its Appendix 4C for the quarter ending 31 March 2026.

Highlights

- Customer receipts: \$2.2m for the quarter; \$6.2m for the 9 months to 31 March 2026.
- Positive net operating cash flow: \$14k for the quarter, compared with \$(95)k in Q2 FY26.
- Closing cash of \$837k at 31 March 2026, up from \$669k at 31 December 2025.
- Capital raising announced on 11th March to raise approximately \$2.2m before costs via a two-tranche placement of approximately 440.0m new shares at \$0.005 per share.
- EHS sale completed post quarter-end: 9th April 2026
- EHS vendor loan repaid: Approximately \$2.47m was applied from EHS settlement proceeds to fully repay the EHS vendor loan and outstanding interest.
- HMR Referrals strategic reset: The Company is now focused on refining and executing a revised business plan for HMR Referrals which will also explore staged AI-enablement and functionality where it adds measurable value.
- ATO R&D – Formal objection process commenced with additional evidence submitted including key staff witness statements now sitting with the ATO's Objection Officer for their review.

Strategic Reset

The March quarter was a significant transition period for Careteq. The Company delivered positive operating cash flow for the quarter while progressing two important balance sheet and strategic initiatives: the divestment of Embedded Health Solutions (EHS) and the completion of a two-tranche capital raising.

Operational Performance

For the quarter, Careteq reported customer receipts of \$2.192m, compared with \$2.098m in the prior quarter, and generated positive net operating cash flow of \$14k, improving from a \$95k operating cash outflow in the December quarter.

Cash at quarter end was \$837k, compared with \$669k at 31 December 2025. The positive operating cash flow result reflects continued working capital discipline and operating cost control during the transition period leading into completion of the EHS divestment.

Embedded Health Solutions (EHS) Sale Completed

Subsequent to quarter end, Careteq completed the sale of EHS to Nationwide Investments Holdings Pty Ltd, on 9 April 2026 for \$5.0m less customary purchase price adjustments, including working capital and employee entitlement adjustments totalling approximately \$990k. This enables the Company to recalibrate its balance sheet and focus on the growth of HMR Referrals, now Careteq's sole remaining marketplace platform.

Capital raising and balance sheet strengthening

During the quarter, Careteq announced that it had received commitments from new and existing institutional and sophisticated investors to raise approximately \$2.2m before costs through a two-tranche placement of approximately 440,000,000 fully paid ordinary shares at an issue price of \$0.005 per share. The placement was structured as:

- Tranche 1: approximately \$193k before costs, via the issue of 38,632,636 new shares under the Company's existing placement capacity; and
- Tranche 2: approximately \$2.07m before costs, via the issue of 401,367,364 new shares, approved by shareholders at General Meeting held on the 23rd April 2026.

HMR Referrals

The Board and management are well underway on re-crafting the HMR Referrals business plan to reflect the platform's position as Careteq's sole remaining operating business. The revised plan is expected to focus on:

- accelerating referral growth through GP networks, accredited pharmacists, home care providers and disability-sector channels;
- assessing technology and platform requirements to support scale, workflow efficiency and compliance, including the staged exploration of AI-enabled functionality where it can deliver measurable value to referrers, pharmacists and end-clients;
- aligning the operating cost base to a streamlined, HMR-focused business;
- pursuing partnership opportunities that can broaden referral pathways; and
- determining capital allocation priorities following the EHS sale and capital raising.

The Company's objective is to position HMR Referrals as a focused, scalable and progressively technology-enabled platform in the home medication review sector while maintaining disciplined overhead management and preserving balance sheet flexibility.

Board Remuneration

The Board has determined that post the sale of EHS, completion of the capital raise and the re-crafting of the HMR Referrals business plan, it is important that Director remuneration aligns appropriately. This has resulted in all members of the Board agreeing to a revised remuneration from the 1st May 2026. Details provided below:

Mark Simari – Executive Chair/CEO

- \$120,000 per annum (inclusive of superannuation) – previously \$240,000 per annum (inclusive of superannuation)

Stephen Munday – Non-Executive Director

- \$30,000 per annum (inclusive of superannuation) – previously \$36,000 per annum (inclusive of superannuation)

Brett Cheong – Non-Executive Director

- \$30,000 per annum (inclusive of superannuation) – previously \$36,000 per annum (inclusive of superannuation)

ATO position update

Formal ATO objection process commenced for the previously disclosed ATO issued amended assessments relating to R&D Tax Incentive claims for FY21–FY23. Careteq with the support of its legal advisors, has lodged its submission including key staff witness statements as additional evidence to support its defence. The matter is currently sitting with the ATO's Objection Officer for their review.

The Board will keep shareholders and the market informed as appropriate.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)

For further information, please contact:

Careteq Limited (ASX: CTQ)

Mark Simari
Executive Chairman
P: +61 3 8866 5594
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company focused on innovative solutions for the home care and disability sector. The Company is dedicated to improving healthcare outcomes through its fully owned marketplace platform, HMR Referrals which streamlines the process of completing Home Medicines Reviews (HMRs).

To learn more, please visit: www.careteq.com.au/

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs,

assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information

Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Careteq Limited

ABN

83 612 267 857

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,192	6,213
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(61)	(114)
(c) advertising and marketing	(7)	(37)
(d) leased assets	-	-
(e) staff costs	(1,691)	(4,957)
(f) administration and corporate costs	(411)	(1,416)
1.3 Dividends received	-	-
1.4 Interest received	-	4
1.5 Interest and other costs of finance paid	(6)	(23)
1.6 Income taxes paid	-	(24)
1.7 Government grants and tax incentives	(2)	5
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	14	(349)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(22)	(63)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	—	—
	(b) businesses	—	—
	(c) property, plant and equipment	—	—
	(d) investments	—	—
	(e) intellectual property	—	—
	(f) other non-current assets	—	—
2.3	Cash flows from loans to other entities	—	—
2.4	Dividends received (see note 3)	—	—
2.5	Other (provide details if material)	—	—
2.6	Net cash from / (used in) investing activities	(22)	(63)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	193	193
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	—	—
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(18)	(18)
3.5	Proceeds from borrowings	—	47
3.6	Repayment of borrowings	—	—
3.7	Transaction costs related to loans and borrowings	—	—
3.8	Dividends paid (Note 3)	—	—
3.9	Other (provide details if material)	—	—
3.10	Net cash from / (used in) financing activities	175	222

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	669	1,027
4.2	Net cash from / (used in) operating activities (item 1.9 above)	14	(349)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(22)	(63)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	175	222
4.5	Effect of movement in exchange rates on cash held	1	—
4.6	Cash and cash equivalents at end of period	837	837

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	837	669
5.2	Call deposits	—	—
5.3	Bank overdrafts	—	—
5.4	Other (provide details)	—	—
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	837	669

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	113
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

C

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	125	125
7.2	Credit standby arrangements	—	—
7.3	Other (Convertible Note)	356	356
7.4	Total financing facilities	481	481
7.5	Unused financing facilities available at quarter end		0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. As announced to the market on 10 and 13 June 2025, the Company entered in a binding convertible note agreement with Mr Antanas Guoga (Tony G) for \$500,000. The note carries a coupon rate of 12% per annum, which is included in the face value and is payable through the issue of fully paid ordinary shares in Careteq Ltd at a conversion price of \$0.01 per share. The notes will mature on 4 June 2026. On 25 February 2026, shares were issued to Mr Antanas Guoga, reducing his Convertible note balance to \$355,678. Further, as announced on 10 June 2025, all members of the Board including its Company Secretary entered into a binding loan agreement to raise \$125,000. The interest rate on each loan is 12% per annum and mature on 4 June 2026. The breakdown is as follows: • Mr Mark Simari (Executive Chair) – loan amount of \$26,500 • Mr Brett Cheong (Non-Executive Director) – loan amount of \$26,500 • Mr Stephen Munday (Non-Executive Director) – loan amount of \$47,000 • Mr David Lilja (Company Secretary) – loan amount of \$26,500		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	14
8.2	Cash and cash equivalents at quarter end (item 4.6)	837
8.3	Unused finance facilities available at quarter end (item 7.5)	—
8.4	Total available funding (item 8.2 + item 8.3)	837
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer:	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:30th April 2026.....

Authorised by:By the Board of Directors of Careteq Limited.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends paid may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.